Zang MY - Search Results

1

[Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: a multicenter retrospective study].

Yuan GS, He WM, Hu XY, Li Q, Zang MY, Cheng X, Huang W, Ruan J, Wang JJ, Hou JL, Chen JZ. Yuan GS, et al. Among authors: zang my. Zhonghua Gan Zang Bing Za Zhi. 2021 Apr 20;29(4):326-331. doi: 10.3760/cma.j.cn501113-20210329-00148. Zhonghua Gan Zang Bing Za Zhi. 2021. PMID: 33979958 Chinese.

2

Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.

Yuan G, Cheng X, Li Q, Zang M, Huang W, Fan W, Wu T, Ruan J, Dai W, Yu W, Chen M, Guo Y, Hu X, Chen J. Yuan G, et al. Onco Targets Ther. 2020 Dec 9;13:12683-12693. doi: 10.2147/OTT.S286169. eCollection 2020. Onco Targets Ther. 2020. PMID: 33328740 Free PMC article.

3

Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients.

Yuan G, Song Y, Li Q, Hu X, Zang M, Dai W, Cheng X, Huang W, Yu W, Chen M, Guo Y, Zhang Q, Chen J. Yuan G, et al. Front Immunol. 2021 Jan 8;11:613946. doi: 10.3389/fimmu.2020.613946. eCollection 2020. Front Immunol. 2021. PMID: 33488622 Free PMC article.

4

Interaction between hepatitis B virus infection and the efficacy of camrelizumab in combination with apatinib therapy in patients with hepatocellular carcinoma: a multicenter retrospective cohort study.

Yuan G, Li R, Li Q, Hu X, Ruan J, Fan W, Wang J, Huang W, Zang M, Chen J. Yuan G, et al. Ann Transl Med. 2021 Sep;9(18):1412. doi: 10.21037/atm-21-3020. Ann Transl Med. 2021. PMID: 34733964 Free PMC article.

5

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study.

Li Q, Cao M, Yuan G, Cheng X, Zang M, Chen M, Hu X, Huang J, Li R, Guo Y, Ruan J, Chen J. Li Q, et al. Front Oncol. 2022 Feb 24;12:809709. doi: 10.3389/fonc.2022.809709. eCollection 2022. Front Oncol. 2022. PMID: 35280760 Free PMC article.

6

Hepatic Tumor Stiffness Measured by Shear Wave Elastography Is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts.

Yuan G, Xie F, Song Y, Li Q, Li R, Hu X, Zang M, Cheng X, Lu G, Huang J, Fan W, Rong X, Sun J, Chen J. Yuan G, et al. Front Immunol. 2022 Jun 9;13:868809. doi: 10.3389/fimmu.2022.868809. eCollection 2022. Front Immunol. 2022. PMID: 35757765 Free PMC article.

7

Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.

Hu X, Li R, Li Q, Zang M, Yuan G, Chen J. Hu X, et al. BMC Infect Dis. 2022 Jul 14;22(1):614. doi: 10.1186/s12879-022-07602-0. BMC Infect Dis. 2022. PMID: 35836207 Free PMC article.

8

Characterization of somatic mutations and pathway alterations during hepatocellular carcinoma vascular invasion using next-generation sequencing.

Li Q, Zhang Q, Chen J, Zang M, Hu X, Li R, Hou J, Zhou J. Li Q, et al. J Gastrointest Oncol. 2022 Aug;13(4):1864-1874. doi: 10.21037/jgo-22-556. J Gastrointest Oncol. 2022. PMID: 36092348 Free PMC article.

9

Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study.

Zang M, Hu X, Yuan G, Li R, Li W, Pang H, Li Q, Chen J. Zang M, et al. Int Immunopharmacol. 2023 Dec;125(Pt A):111019. doi: 10.1016/j.intimp.2023.111019. Epub 2023 Oct 24. Int Immunopharmacol. 2023. PMID: 37879230 Free article.

10

Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study.

Yuan G, Li W, Zang M, Li R, Li Q, Hu X, Zhang Q, Huang W, Ruan J, Pang H, Chen J. Yuan G, et al. Discov Oncol. 2024 Mar 9;15(1):68. doi: 10.1007/s12672-024-00917-1. Discov Oncol. 2024. PMID: 38460053 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

22 results

Search Page